Severe Eosinophilic Asthma Clinical Trial
Official title:
Utilisation of Benralizumab in the Clinical Practise in Severe Eosinophilic Asthma Patients in Switzerland
BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1 to 16 weeks post-treatment initiation including use of OCS. The generated data on the time of asthma symptom relief after initiation of benralizumab will support patient management for a better disease control in severe asthma patients under benralizumab treatment. To assess long term outcomes the patients will have a last mandatory visit after 56 weeks, with no visits scheduled between week 16 and 56.
The aim and objective of this single arm, prospective observational study is to describe patient reported outcomes (PRO) in severe eosinophilic asthma patients who are treated with benralizumab according to the label granted in Switzerland. The PRO measures consist of the weekly Asthma Control Questionnaire (ACQ-5) as well as Patient Global Impression of Change and Severity (PGI-C and PGI-S) collected at each visit (0, 1, 2, 4, 8, 16, 56 weeks). In addition the patient fills out twice daily the patient electronic asthma diary (eDiary) capturing daily symptoms and symptom free days together with a PEF (Peak Expiratory Flow) measurement. Persistance with eDiary and PEF will be assessed after 56 weeks. The percentage of patients successfully reducing their OCS dose will be evaluated after 16 weeks of treatment with benralizumab and if OCS reduction is persistent until week 56. Furthermore, the proportion of patients with an ACQ-5 score improvement of ≥ 0.5 after 8 weeks of treatment with benralizumab will be determined. In addition, the study will assess changes in FEV1 and FVC after 8, 16 and 56 weeks of treatment with benralizumab and describe retrospectively asthma disease history, past treatment status and current medication at baseline. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
| Completed |
NCT02560610 -
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
|
Phase 2 | |
| Recruiting |
NCT06069310 -
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
|
||
| Not yet recruiting |
NCT03652376 -
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
|
Phase 4 | |
| Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
| Completed |
NCT05180357 -
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
|
||
| Active, not recruiting |
NCT03833141 -
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
|
||
| Completed |
NCT05271526 -
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
|
||
| Not yet recruiting |
NCT06302959 -
Clock Proteins as Prognostic Markers
|
||
| Recruiting |
NCT05440656 -
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
|
||
| Completed |
NCT04159519 -
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
|
Phase 4 | |
| Active, not recruiting |
NCT04084613 -
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
|
||
| Completed |
NCT04126499 -
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
|
||
| Recruiting |
NCT03739320 -
A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
|